Clinical trial
A Study of Lerociclib in Participants With Advanced Breast Cancer
NCT05085002 · EQRx, Inc., Industry · Terminated
Key facts
| NCT number | NCT05085002 |
|---|---|
| Title | A Study of Lerociclib in Participants With Advanced Breast Cancer |
| Official title | A Phase 2 Study to Evaluate the Safety and Efficacy of Lerociclib in Participants With Advanced Breast Cancer |
| Lead sponsor | EQRx, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Breast Cancer |
| Intervention type | Drug |
| Interventions | Lerociclib + Letrozole or Fulvestrant |
| Enrollment | 100 |
| Start date | Dec 21, 2021 |
| Primary completion | Nov 29, 2023 |
| Completion | Nov 29, 2023 |
| First posted | Oct 20, 2021 |
| Last update posted | Mar 12, 2024 |
| Countries | Belgium, Georgia, Italy, Mexico, Moldova, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: